HK Stock Market Move | SKB BIO-B(06990) is now falling by over 4%, with TSLP monoclonal antibody reaching approximately $1 billion in overseas cooperation. Institutions have slightly lowered the company's target price.

SKB BIO-B (06990) is currently down more than 4%, as of the time of writing, it is down 3.94% at 163.2 Hong Kong dollars, with a trading volume of 15.46 million Hong Kong dollars. On the news front, SKB378 is a TSLP monoclonal antibody jointly developed by Corun Pharma and Hepu Pharma, which has now been licensed to Windward Company. The transaction value can reach as high as 970 million dollars, including a down payment of 45 million dollars and recent payments to be made in cash and Windward's parent company's equity, with Corun Pharma and Hepu Pharma splitting the payments. CMB International released a research report maintaining a "buy" rating for Corun Pharma. They are optimistic about SKB264 reaching a sales target of 800 million to 1 billion Chinese Yuan in 2025, and expect SKB264 to be approved this year for second-line/third-line EGFR-TKI-resistant non-small cell lung cancer. They have also revised the target price for the company from 243.38 Hong Kong dollars to 227.88 Hong Kong dollars.